|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
WO1992008796A1
(en)
|
1990-11-13 |
1992-05-29 |
Immunex Corporation |
Bifunctional selectable fusion genes
|
|
AU6953394A
(en)
|
1993-05-21 |
1994-12-20 |
Targeted Genetics Corporation |
Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
|
|
US5814618A
(en)
|
1993-06-14 |
1998-09-29 |
Basf Aktiengesellschaft |
Methods for regulating gene expression
|
|
US5464758A
(en)
|
1993-06-14 |
1995-11-07 |
Gossen; Manfred |
Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
|
|
PT1210428E
(pt)
|
1999-08-23 |
2015-07-21 |
Genetics Inst Llc |
Pd-1, um recetor para b7-4 e suas utilizações
|
|
EP1320599A2
(en)
|
2000-06-28 |
2003-06-25 |
Genetics Institute, LLC |
Pd-l2 molecules: pd-1 ligands and uses therefor
|
|
FR2814642B1
(fr)
|
2000-10-03 |
2005-07-01 |
Ass Pour Le Dev De La Rech En |
Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
|
|
US7414171B2
(en)
|
2000-11-15 |
2008-08-19 |
Ono Pharmaceutical Co., Ltd. |
PD-1-lacking mouse and use thereof
|
|
WO2002079499A1
(en)
|
2001-04-02 |
2002-10-10 |
Wyeth |
Pd-1, a receptor for b7-4, and uses therefor
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
US20040241745A1
(en)
|
2001-07-31 |
2004-12-02 |
Tasuku Honjo |
Substance specific to pd-1
|
|
CA2466279A1
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
PT1537878E
(pt)
|
2002-07-03 |
2010-11-18 |
Ono Pharmaceutical Co |
Composições de imunopotenciação
|
|
WO2004056875A1
(en)
|
2002-12-23 |
2004-07-08 |
Wyeth |
Antibodies against pd-1 and uses therefor
|
|
WO2004072286A1
(ja)
|
2003-01-23 |
2004-08-26 |
Ono Pharmaceutical Co., Ltd. |
ヒトｐｄ−１に対し特異性を有する物質
|
|
PL2161336T5
(pl)
|
2005-05-09 |
2017-10-31 |
Ono Pharmaceutical Co |
Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
|
|
KR101510065B1
(ko)
|
2005-06-08 |
2015-04-07 |
다나-파버 캔서 인스티튜트 인크. |
예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
|
|
US8901281B2
(en)
|
2005-06-17 |
2014-12-02 |
Merck Sharp & Dohme Corp. |
ILT3 binding molecules and uses therefor
|
|
EP2468765B1
(en)
|
2006-03-03 |
2015-04-22 |
ONO Pharmaceutical Co., Ltd. |
Tetramer of extracellular domain of PD-L1
|
|
WO2008060364A2
(en)
*
|
2006-10-02 |
2008-05-22 |
Ac Immune S.A |
Humani zed antibody against amyloid beta
|
|
CA2947292C
(en)
|
2006-12-27 |
2019-07-23 |
Emory University |
Compositions and methods for the treatment of infections and tumors
|
|
EA016079B1
(ru)
|
2007-01-10 |
2012-01-30 |
Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа |
Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
|
|
NZ579010A
(en)
|
2007-02-20 |
2012-03-30 |
Anaptysbio Inc |
Somatic hypermutation systems
|
|
KR101123487B1
(ko)
|
2007-03-20 |
2012-03-23 |
일라이 릴리 앤드 캄파니 |
항?스클레로스틴 항체
|
|
KR100897938B1
(ko)
|
2007-05-30 |
2009-05-18 |
주식회사 제넥신 |
면역글로불린 융합 단백질
|
|
KR101586617B1
(ko)
|
2007-06-18 |
2016-01-20 |
머크 샤프 앤 도메 비.브이. |
사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
|
|
US20090028857A1
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
|
US20120269806A1
(en)
|
2007-08-21 |
2012-10-25 |
The General Hospital Corporation |
Methods of inducing tolerance
|
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
|
EP2650308A3
(en)
|
2007-10-05 |
2014-11-12 |
Genentech, Inc. |
Use of anti-amyloid beta antibody in ocular diseases
|
|
NZ586675A
(en)
|
2008-01-08 |
2012-04-27 |
Merck Sharp & Dohme |
Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
WO2010001617A1
(en)
|
2008-07-04 |
2010-01-07 |
Ono Pharmaceutical Co., Ltd. |
Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
ES2545609T3
(es)
|
2008-08-25 |
2015-09-14 |
Amplimmune, Inc. |
Composiciones de antagonistas de PD-1 y métodos de uso
|
|
CA2736829C
(en)
|
2008-09-12 |
2018-02-27 |
Isis Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
|
JP5794917B2
(ja)
|
2008-09-12 |
2015-10-14 |
アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ |
Ｐｄ−１特異抗体およびその使用
|
|
PL2342226T3
(pl)
|
2008-09-26 |
2017-01-31 |
Dana-Farber Cancer Institute, Inc. |
Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
|
|
KR101050829B1
(ko)
|
2008-10-02 |
2011-07-20 |
서울대학교산학협력단 |
항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
|
|
EP2370593B1
(en)
|
2008-11-28 |
2016-03-30 |
Emory University |
Methods for determining the efficacy of pd-1 antagonists
|
|
EP3192811A1
(en)
|
2009-02-09 |
2017-07-19 |
Université d'Aix-Marseille |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
CA2779384C
(en)
*
|
2009-11-04 |
2018-02-27 |
Schering Corporation |
Engineered anti-tslp antibody
|
|
SI2519543T1
(sl)
|
2009-12-29 |
2016-08-31 |
Emergent Product Development Seattle, Llc |
Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
|
|
CA2790134A1
(en)
|
2010-02-16 |
2011-08-25 |
Valorisation-Recherche, Limited Partnership |
Pd-1 modulation and uses thereof for modulating hiv replication
|
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
EP2545078A1
(en)
|
2010-03-11 |
2013-01-16 |
UCB Pharma, S.A. |
Pd-1 antibody
|
|
US20130035472A1
(en)
|
2010-03-17 |
2013-02-07 |
Anaptysbio, Inc. |
Method of producing transcripts using cryptic splice sites
|
|
EP2547365A1
(en)
|
2010-03-17 |
2013-01-23 |
Abbott Research B.V. |
Anti-nerve growth factor (ngf) antibody compositions
|
|
CA2802344C
(en)
|
2010-06-18 |
2023-06-13 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
|
MX2013001305A
(es)
|
2010-08-05 |
2013-03-20 |
Hoffmann La Roche |
Proteina de fusion de citoquina anti-viral de anticuerpo anti-mhc.
|
|
EP2603610A4
(en)
|
2010-08-12 |
2014-02-26 |
Beth Israel Hospital |
METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING A LUPUS
|
|
US20130310266A1
(en)
|
2010-09-03 |
2013-11-21 |
Immport Therapeutics, Inc. |
Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders
|
|
CN103261217B
(zh)
|
2010-11-11 |
2017-04-26 |
港大科桥有限公司 |
可溶性 pd‑1变体、融合构建体及其用途
|
|
US9402916B2
(en)
|
2011-03-17 |
2016-08-02 |
The University Of Birmingham |
Re-directed immunotherapy
|
|
MX341076B
(es)
|
2011-03-31 |
2016-08-04 |
Merck Sharp & Dohme |
Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
|
|
TWI496886B
(zh)
|
2011-06-24 |
2015-08-21 |
Taipei Veteran General Hospital |
提升感染性與惡性疾病之治療之免疫反應
|
|
EP2739358B1
(en)
|
2011-08-01 |
2018-11-28 |
F.Hoffmann-La Roche Ag |
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
US9701749B2
(en)
|
2011-08-11 |
2017-07-11 |
Ono Pharmaceutical Co., Ltd. |
Therapeutic agent for autoimmune diseases comprising PD-1 agonist
|
|
WO2013025779A1
(en)
|
2011-08-15 |
2013-02-21 |
Amplimmune, Inc. |
Anti-b7-h4 antibodies and their uses
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
WO2013169693A1
(en)
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
|
|
AU2013263076B2
(en)
|
2012-05-15 |
2017-08-31 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
|
US20150079192A1
(en)
|
2012-05-21 |
2015-03-19 |
Marv Enterprises, LLC |
Treatment of cancer by manipulating the immune system
|
|
WO2013174997A1
(en)
|
2012-05-25 |
2013-11-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of refractory haematological malignancies
|
|
JP6312659B2
(ja)
|
2012-05-31 |
2018-04-18 |
ジェネンテック， インコーポレイテッド |
Ｐｄ−１系結合アンタゴニスト及びｖｅｇｆアンタゴニストを用いた癌の治療方法
|
|
JP6742903B2
(ja)
*
|
2013-05-02 |
2020-08-19 |
アナプティスバイオ インコーポレイティッド |
プログラム死−１（ｐｄ−１）に対する抗体
|
|
HUE046249T2
(hu)
|
2013-12-12 |
2020-02-28 |
Shanghai hengrui pharmaceutical co ltd |
PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
CA2935423C
(en)
|
2014-01-24 |
2023-11-07 |
Dana-Farber Cancer Institute, Inc. |
Antibody molecules to pd-1 and uses thereof
|
|
EP3114144A1
(en)
|
2014-03-05 |
2017-01-11 |
Bristol-Myers Squibb Company |
Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
|
WO2015138920A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
CN107172880B
(zh)
|
2014-03-24 |
2021-09-28 |
癌症研究技术有限公司 |
含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
|
|
EP3683238A1
(en)
|
2014-06-19 |
2020-07-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized programmed cell death 1 gene
|
|
CA2957258C
(en)
|
2014-08-05 |
2023-11-07 |
MabQuest SA |
Immunological reagents
|
|
US20170247455A1
(en)
*
|
2014-08-22 |
2017-08-31 |
Bristol-Myers Squibb Company |
Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
|
|
KR20170066546A
(ko)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
조합 요법
|
|
US20160176962A1
(en)
|
2014-10-31 |
2016-06-23 |
Oncomed Pharmaceuticals, Inc. |
Combination Therapy For Treatment Of Disease
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
MA41217A
(fr)
|
2014-12-19 |
2017-10-24 |
Advaxis Inc |
Polythérapies ayant des souches de listeria recombinées
|
|
DK3237446T3
(en)
|
2014-12-22 |
2021-07-26 |
Pd 1 Acquisition Group Llc |
Anti-PD-1-antistoffer
|
|
SI3240801T1
(sl)
|
2014-12-31 |
2021-04-30 |
Checkmate Pharmaceuticals, Inc. |
Kombinirana imunoterapija tumorja
|
|
CN107106683B
(zh)
|
2015-01-16 |
2021-07-20 |
中央研究院 |
含靶向与效应组件的分子构建体
|
|
MA41463A
(fr)
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
|
EP3277321B1
(en)
|
2015-04-01 |
2024-08-14 |
AnaptysBio, Inc. |
Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
|
|
MY188749A
(en)
*
|
2015-04-17 |
2021-12-28 |
Bristol Myers Squibb Co |
Compositions comprising a combination of nivolumab and ipilimumab
|
|
WO2016176504A1
(en)
|
2015-04-28 |
2016-11-03 |
Bristol-Myers Squibb Company |
Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
|
|
ES2878188T3
(es)
|
2015-07-29 |
2021-11-18 |
Novartis Ag |
Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
|
|
FI3478286T3
(fi)
|
2016-06-29 |
2024-03-14 |
Tesaro Inc |
Menetelmiä munasarjasyövän hoitamiseksi
|
|
SG11201903867YA
(en)
|
2016-11-01 |
2019-05-30 |
Anaptysbio Inc |
Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
|
|
EP3666794A1
(en)
*
|
2016-11-01 |
2020-06-17 |
AnaptysBio, Inc. |
Antibodies directed against programmed death- 1 (pd-1)
|
|
EA201990741A1
(ru)
|
2016-11-29 |
2019-11-29 |
|
Антитела, направленные против белка-1 запрограммированной смерти (pd-1)
|
|
JP7118073B2
(ja)
|
2017-01-09 |
2022-08-15 |
テサロ， インコーポレイテッド |
抗ｔｉｍ－３抗体を用いてがんを処置する方法
|
|
EP3565844B8
(en)
|
2017-01-09 |
2023-04-12 |
Tesaro, Inc. |
Methods of treating cancer with anti-pd-1 antibodies
|
|
KR20200086664A
(ko)
|
2017-09-30 |
2020-07-17 |
테사로, 인코포레이티드 |
암을 치료하기 위한 조합 요법
|
|
TWI852940B
(zh)
|
2018-09-04 |
2024-08-21 |
美商泰沙羅公司 |
治療癌症之方法
|